


OCT.. 4.2004 2:28PM BMS PATENT 203 677 6900

NO.085 P.1

RECEIVED
CENTRAL FAX CENTER

OCT 04 2004

FACSIMILE TRANSMISSION




BRISTOL-MYERS SQUIBB COMPANY
Legal Division
P.O. Box 5100
5 Research Parkway
Wallingford, CT 06492-7660

TO: Zinna Northington Davis, USPTO
FAX NO: 1-703-872-9306
FROM: James Epperson, Bristol-Myers Squibb (203-677-6974)
FAX NO: 203-677-6900
TOTAL NUMBER OF PAGES INCLUDING THIS ONE: 7
DATE: October 4, 2004
RE: US application 10/812,245
COMMENTS: Reply to office action

OCT.. 4. 2004 2:28PM BMS PATENT 203 677 6900

NO.085 P.2

Docket Number		CT-2477 NP
CERTIFICATE OF FACSIMILE TRANSMISSION		
I hereby certify that this paper, along with any paper referred to as being attached or enclosed, is being facsimile transmitted to the United States Patent and Trademark Office on the date shown below.		
James Epperson Type or print name	 Signature	October 4, 2004 Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF Dubowchik et al.

APPLICATION NO: 10/812,245

FILED: 03/29/2004

FOR: Tetrahydroisoquinoline derivatives as melatonin MT₂ antagonists

EXAMINER: Zinna Northington Davis

ART UNIT: 1625

RECEIVED
CENTRAL FAX CENTER

OCT 04 2004

MAIL STOP: Amendments
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Reply and request for reconsideration under 37 CFR 1.111

Sir:

We received the Office Action dated September 16, 2004 setting a three month shortened statutory response period ending December 16, 2004. In response, the applicants submit the following amendments and remarks and respectfully request reconsideration of the application.